KAROLINSKA INSTITUTET

List of publications
Svetlana Bajalica Lagercrantz

List of all original works
Underline indicate students and postdocs under direct supervision of the applicant

1) E. Ehrenborg, S. Vilhemsdotter, **S. Bajalica**, C. Larsson, I. Steern, J. Koch, K. Brøndum Nielsen, H. Luthman: Structure and localization of the human insulin-like growth factor-binding protein 2 gene. *Biochemical Biophysical Research Communication*, 1991 (176) 3:1250-1255.
2) **S. Bajalica**, T-H. Bui, J Koch, K. Brøndum Nielsen: Prenatal investigation of a 45,X/46,X,r(?) karyotype in amniocytes, demonstrating the origin of the ring chromosome using fluorescence in situ hybridization with an X-centromere probe. *Prenatal Diagnosis*, 1992 (12) 61-64.
3) **S. Bajalica**, SV. Allander, E. Ehrenborg, K. Brøndum Nielsen, H. Luthman, C. Larsson: Localization of the human insulin-like growth factor-binding protein 4 gene to chromosomal region 17q12-21.2. *Human Genetics*, 1992 (89) 234-236.
4) E. Blennow, H. Telenius, C Larsson, D. de Vos, **S. Bajalica**, BAJ. Ponder, NP. Carter: Complete characterization of a large marker chromosome by reverse and forward chromosome painting. *Human Genetics*, 1992 (90) 371-374.

Thesis paper I

5) **S. Bajalica**, K. Brøndum Nielsen, A-G. Sørensen, N. Tinggaard Petersen, S. Heim: Identification of a whole arm translocation by in situ hybridization with direct fluorochrome-labeled probes in MDS. *Genes Chromosomes and Cancer*, 1992 (5) 128-131.

Thesis paper II

6) **S. Bajalica**, A-G. Sørensen, N. Tingaard Pedersen, S. Heim, K. Brøndum-Nielsen: Chromosome painting as a supplement to cytogenetic banding analysis in non-Hodgkin´s lymphoma. *Genes Chromosomes and Cancer*, 1993 (7) 231-239.
7) SV Allander, **S. Bajalica**, C. Larsson, H. Luthman, DR. Powell, I. Stern, G. Weber, H. Zazzi, E. Ehrenborg: Structure and chromosomal localization of human insulin-like growth factor binding protein genes. *Growth Regulation*, 1993 (3) 3-5.
8) K. Brøndum-Nielsen, **S. Bajalica**, K. Wullf, M. Mikkelsen: Chromosome painting using FISH (fluorescence in situ hybridization) with chromosome-6-specific library demonstrates the origin of a de novo 6q+ marker chromosome. *Clinical Genetics*, 1993 (43) 235-239.
9) SV. Allander, C. Larsson, E. Ehrenborg, A. Suwanichkul, G. Weber, S. L. Morris, **S. Bajalica**, MC. Kiefer, H. Luthman, DR. Powell: Characterization of the chromosomal gene and promotor for insulin-like growth factor binding protein-5. *Journal of Biological Chemistry*, 1994 (269) 10891-10898.
10) Y-T. Wang, **S. Bajalica**, F-Y. Han, Z-C. Wang, T-H. Bui, Y-G. Xie: Direct and inverted reciprocal chromosome insertions between chromosome 7 and 14 in a woman with recurrent miscarriages. *American Journal of Medical Genetics*, 1994 (52) 349-351.
11) Y-G. Xie, F-Y. Han, **S. Bajalica**, E. Blennow, U. Kristoffersson, J. P. Dumanski, M. Nordenskjöld: Identification, characterization and clinical applications of cosmids from the telomeric and centromeric regions of the long arm of

chromosome 22. *Human Genetics*, 1994 (94) 339-345.

Thesis paper III

12) **S. Bajalica**, K. Brøndum-Nielsen, A-G. Sørensen, N. Tinggaard Pedersen, U. Kristoffersson, M. Åkerman, M. Anderson, P. Pisa, M. Nordenskjöld: Characterization of add(1)(p36) in non-Hodgkin Lymphomas by Fluorescence In Situ Hybridization. *Genes Chromosomes and Cancer*, 1995 (13) 34-39.
13) **S. Bajalica**, E. Blennow, A. Tsezou, A. Galla-Voumvouraki, M. Alevizaki, C. Sinaniotis, S. Kitsiou-Tzeli: Partial disomy of Xp and the presence of SRY in a phenotypic female. *Journal of Medical Genetics* 1995 (32) 987-990.
14) CA. Padilla, **S. Bajalica**, J. Lagercrantz, A. Holmgren: The gene for human glutaredoxin (GLRX) is localized to human chromosome 5q14. *Genomics* 1996 (32) 455-457.
15) X. Xu, J. Lagercrantz, P. Zickert, **S. Bajalica-Lagercrantz**, A. Zetterberg: Chromosomal localization and 5' sequence of the human proteinserine/ threoninephosphatase 5 (Pp5) gene. *Biochemical and Biophysical Research Communications* 1996 (218) 514-517.

Thesis paper IV

16) **S. Bajalica-Lagercrantz**, N. Tinggaard Pedersen, A-G. Sørensen, M. Nordenskjöld: A duplication of 2q31-qter as a Sole Aberration In a Case of non-Hodgkin Lymphoma. *Cancer Genetics and Cytogenetics*, 1996 (90) 102-105.
17) A. Szeles, **S. Bajalica-Lagercrantz**, A. Lindblom, T. Lushnikova, V. I. Kashuba, S. Imreh, M. Nordenskjöld, G. Klein, E. R. Zabarovsky: Mapping of a new MAP kinase activated protein kinase gene (3pK) to human chromosome band 3p21.2 and ordering of 3pK and two cosmid markers in 3p22-p21 tumor suppressor region by two color FISH. *Chromosome Research*, 1996 (4) 310-313.
18) J. Lagercrantz and **S. Lagercrantz:** Nucleotide Sequence of a cDNA clone (SUBT1) partly homologous to a Human Subtelomeric Repeat Sequence. *Biochemistry and Molecular Biology International*, 1996 (39) 2:303-306. 2013
19) A, Simon, J. Lagercrantz, **S. Bajalica-Lagercrantz**, U. Eriksson: Primary structure of human 11-cis retinol dehydrogenase and organization and chromosomal localization of the corresponding gene. *Genomics* 1996 (36) 424-430.
20) M. Johansson, **S. Bajalica-Lagercrantz**, J. Lagercrantz, A. Karlsson: Localization of the human deoxyguanosine kinase gene (DGUOK) to chromosome 2p13.
Genomics, 1996 (38) 450-451.

Thesis paper V

21) **S. Bajalica-Lagercrantz**, F. Piehl, J. Lagercrantz, J. Lindahl, G. Weber, J. P. Kerckaert, A. Porwit-McDonald, M. Nordenskjöld: Expression of LAZ3/BCL6 in follicular center (FC) B cells of reactive lymph nodes and FC-derived non-Hodgkin lymphomas.
Leukemia, 1997 (11) 594-598.
22) A. Cederberg, R. Betz, **S. Lagercrantz**, C. Larsson, M. Hulander, P. Carlsson, S. Enerbäck: Chromosomal localization, sequence analysis and expression pattern identifies freac-10 as a novel forkhead gene. *Genomics*, 1997 (44) 344-346.
23) S. Ernstsson, R. Betz, **S. Lagercrantz**, C. Larsson, S. Ericksson, A. Cerdeberg, P. Carlsson, S. Enerbäck: Cloning and characterization of freac-9; a novel kidney-expressed human forkhead gene that maps to chromosome 1p32-34. *Genomics*, 1997 (46) 78-85.
24) E. Enmark, M. Pelto-Huikko, K. Grandien, **S. Lagercrantz**, J. Lagercrantz, G. Frieds, M. Nordenskjöld, J.-Å. Gustafsson: Human estrogen recept-gene structure, chromosomal localisation and expression pattern.

Journal of Clinical Endocrinology and Metabolism, 1997 (82) 4258-4265.
25) R. Betz, B. Leibiger, F. Farnebo, **S. Lagercrantz**, F. Piehl, I. Leibiger, C. Larsson: Mapping of the human Ca2+ channel beta(4) subunit to 2q22-23 and its expression in developing mouse. *Mammalian Genome*, 1998 (9) 310-311.
26) M. Peyrard, S. Parveneh, **S. Lagercrantz**, I. Fransson, S. Sahlen, J. P. Dumanski: Cloning, expression pattern and chromosomal assignment to 16q23 of the human gamma-adaptin gene (ADTG). *Genomics*, 1998 (50) 275-280.
27) **S. Bajalica-Lagercrantz**, F. Piehl, F. Farnebo, C. Larsson, J. Lagercrantz: Expression of the bcl6 gene in the pre- and postnatal mouse. *Biochemical and Biophysical Research Communications*, 1998 (247) 357-360.
28) E. Ehrenborg, H. Zazzi, **S. Lagercrantz**, M. Granqvist, U. Hillerbrand, A. V. Allander, C. Larsson, H. Luthman: Characterization and Chromosomal Localization of the Human Insulin-like Growth Factor-Binding Protein 6 Gene. Mammalian Genome, 1999 (10) 376-380. 2013
29) A. Nordgren, A.-G. Sørensen, N. Tinggaard-Pedersen, E. Blennow, C. Larsson, **S. Lagercrantz**: New Chromosomal Breakpoints in Non-Hodgkin Lymphomas Revealed by Spectral Karyotyping and G-Banding. *International Journal of Molecular Medicine*, 2000 (5) 485-492.
30) P. Kjellman, **S. Lagercrantz**, A. Höög, G. Wallin, C. Larsson, J. Zedenius: Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid cancer. *Genes Chromosomes and Cancer*, 2001 (32) 43-49.
31) L. Forsberg, A. Villablanca, S. Välimäki, F. Farnebo, L-O. Farnebo, **S. Lagercrantz**, C. Larsson: Homozygous inactivation of the MEN1 gene as a specific somatic event in a case of secondary hyperparathyroidism. *European Journal of Endocinology*, 2001 (145) 415-420.
32) L. Forsberg, B. Zablewska, F. Piehl, G. Weber, **S. Lagercrantz**, P. Gaudray, C. Höög, C. Larsson: Differential expression of multiple alternative spliceforms of the Men1 tumor suppressor gene in mouse. *International Journal of Molecular Medicine*, 2001 (8) 681-689.
33) L. Roshani, K. Fujioka, G. Auer, M. Kjellman, **S. Lagercrantz**, C. Larsson: Aberrations of centrosomes in adrenocortical tumors. *International journal of Oncology*, 2002 (6) 1161-1165.
34) M. Berglund, G. Enblad , E. Flordal, W.-O. Lui, C. Backlin, U. Thunberg, C. Sundström, G. Roos, S.V. Allander, M. Erlanson, R. Rosenquist, C. Larsson, **S. Lagercrantz**: Chromosomal imbalances in diffuse large B-cell lymphoma detected by comparative genomic hybridization. *Modern Pathology*, 2002 (8) 807-816.
35) R-M. Amini, M. Berglund, A. Von Heideman, R. Rosenquist, **S. Lagercrantz**, J. Bergh, C. Sundström, B. Glimelius, G. Enblad: A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. *Leukemia and Lymphoma*, 2002 (11) 2179-2189.
36) E. Flordal, M. Berglund, R. Rosenquist, M. Erlanson, G. Enblad, G. Roos, C. Larsson, **S. Lagercrantz**: Clonal development of a blastoid mantle cell lymphoma studied with comparative genomic hybridization. *Cancer Genetics and Cytogenetics*, 2002 (139:1) 38-43.
37) E. Månsson, E. Flordal, J. Liliemark, T. Spasokoukotskaja, H. Elford, **S. Lagercrantz**, S. Eriksson, F. Albertioni: Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. *Biochemical Pharmacology*, 2003 (65) 237-247. 2013
38) M. Berglund, E. Flordal, J. Gullander, W.-O. Lui,, C. Larsson, **S. Lagercrantz**, G. Enblad: Molecular cytogenetic characterization of four commonly used cell

lines derived from Hodgkin lymphoma. *Cancer Genetics and Cytogenetics*, 2003 (141:1) 43-48.
39) J. K. Siwicki, M. Berglund, J. Rygier, B. Pienkowska-Grela, B. Grygalewicz, S. Degerman, I. Golovleva, K. H. Chrzanowska, **S. Lagercrantz**, E. Blennow, G. Roos, C. Larsson: Spontaneously immortalized human T lymphocytes develop gain of chromosomal region 2p13-24 as an early and common genetic event. *Genes, Chromosomes and Cancer*, 2004 (41:2) 133-144.
40) A. Alimov, B. Sundelin, U. Bergerheim, M. Pavlenko, P. Pisa, A. Zetterberg, C. Larsson, **S. Lagercrantz**: Molecular cytogenetic characterization shows higher genetic homogeneity in conventional renal cell carcinoma compared to other kidney cancers. *International Journal of Oncology*, 2004 (25:4) 955-960.
41) E. Flordal, S. H. Walsh, M. Thorselius, A. Laurell, O. Landgren, C. Larsson, R. Rosenquist, **S. Lagercrantz**: Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes. *Modern Pathology*, 2005 (18:3) 331-339.
42) T. Foukakis, S. R. Thoppe, **S. Lagercrantz**, T. Dwight, W.-H. Weng, A. Svensson, A. Höög, J. Zedenius, G. Wallin, W.-O. Lui, C. Larsson: Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors. *International Journal of Oncology* 2005 (26:1)141-149.
43) C. Sambade, M. Berglund, **S. Lagercrantz**, J. Sällström, R. M. Reis, G. Enblad, B. Glimelius, C. Sundström: U-2940: a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma. *International Journal of Cancer* 2005 (118:3)555-563.
44) A. Szeles, S. Joussineau, R. Lewensohn, **S. Lagercrantz**, C. Larsson: Evaluation of spectral karyotyping (SKY) in biodosimetry for the triage situation following gamma irradiation. *International Journal of Radiation Biology* 2006 (82:2) 87-96.
45) E. Flordal Thelander, K. Ichimura, VP. Collins, S. H. Walsh, G. Barbany, A. Hagberg, A. Laurell, R. Rosenquist, C. Larsson, **S. Lagercrantz:** Detailed assessment of copy number alterations revealing homozygous deletions in lp and 13q in mantle cell lymphoma. *Leukemia Research* 2006 (31:9) 1219-30.
46) M. Berglund, G. Enblad, U. Thunberg, R.-M. Amini, C Sundstrom, G. Roos, M. Erlanson, R. Rosenquist, C. Larsson, **S. Lagercrantz:** Genomic imbalances during transformation from follicular lymphoma to diffuse large B-cell lymphoma. *Modern Pathology* 2007 (20:1) 63-75.
47) M. Berglund, U. Thunberg, M. Fridberg, A. G. Wingren, J. Gullbo, KJ. Leuchowius, R-M. Amini, **S. Lagercrantz**, A. Horvat, G. Enblad, O. Soderberg: Establishment of a cell line from a chemotherapy resistant diffuse large B-cell lymphoma. *Leuk Lymphoma* 2007 (48:5) 1038-41.
48) E. Flordal Thelander, K. Ichimura, M. Corcoran, G. Barbany, R.-M. Amini, A. Nordgren, M. Heyman, K. Wester, M. Berglund, A. J. Mungall, R. Rosenquist, V. P. Collins, D. Grandér, C. Larsson, **S. Lagercrantz**: Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia. *Leukemia & Lymphoma* 2008 (49:3), 477-487.
49) A. H. Daneshmanesh, E. Mikaelsson1, M. Jeddi-Tehrani, A. A. Bayat, R. Ghods, M. Ostadkarampour, M. Akhondi, **S. Lagercrantz,** C. Larsson, A. Österborg, F. Shokri, H. Mellstedt, H. Rabbani: Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. *Int J Cancer* 2008 (123:5):1190-5.

50) A. Kwiecinska, K. Ichimura, M. Berglund, A. Dinets, L. Sulaiman, V. P. Collins, C. Larsson, A. Porwit, **S. B. Lagercrantz**: Amplification of 2p as a genomic marker for transformation in lymphoma. *Genes Chromosomes and Cancer* 2014 (53:9):750-68.
51) L. D. Xu, S. Muller, S. R. Thoppe, F. Hellborg, L. Kanter, M. Lerner, B. Zheng, **S. B. Lagercrantz**, D. Grandér, K. L. Wallin, K. G. Wiman, C. Larsson, S. Andersson: *Expression of the p53 target Wig-1 is associated with HPV status and patient survival in cervical carcinoma. PLOS ONE* 2014 *(*9:11):e111125.
52) K Mu, L. Li, Q. Yang, H. Yun, P. Kharaziha; D.-W. Ye, G. Auer, **S. Bajalica Lagercrantz**, and A Zetterberg: A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer. *Annals of Diagnostic Pathology 2015,* 19(4):243-248.
53) X. Zhou, J. Zhang, H. Yun, R. Shi, Y. Wang, W. Wang, **S. Bajalica-Lagercrantz,** K Mu: Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. *Oncotarget 2015,* 6 (34):36894-36902.
54) M. Gnant, G. Pfeiler, PC. Dubsky, M. Hubalek, R. Greil, R. Jakesz, V. Wette, M. Balic, F. Haslbauer, E. Melbinger, V. Bjelic-Radisic, S. Artner-Matuschek, F. Fitzal, C. Marth, P. Sevelda, B. Mlineritsch, GG. Steger, D. Manfreda, R. Exner, D. Egle, J. Bergh, F. Kainberger, S. Talbot, D. Warner, C. Fesl, CF. Singer; Austrian Breast and Colorectal Cancer Study Group, and **S. Bajalica-Lagercrantz** (among 697 collaborators): Adjuvant denosumab in breast cancer (ABCSG-18): a multicenter randomised, double-blind, placebo-controlled trial. *Lancet* 2015, 386 (9992):433-443.
55) P. Pellegrini, M. Dyczynski, F. Vittoria Sbrana, M. Karlgren, M. Buoncervello, M.Hägg-Olofsson, R. Ma, J. Hartman, K. Pokrovskaja Tamm, **S. Bajalica-Lagercrantz**, D. Grandér, P. Kharaziha, A. De Milito: Tumor acidosis enhances autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells. *Oncotarget* 2016, 7(24):35703–35723.
56) Å. Fransson, D. Glaessgen, J. Alfredsson, K. G. Wiman, **S. Bajalica-Lagercrantz** and N. Mohell. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. *J Ovarian Research* 2016, (9) 27-37.
57) A. Kwiecińska, A. Porwit, N. Souchelnytskyi, A. Kaufeldt, C. Larsson, **S. Bajalica-Lagercrantz**, S. Souchelnytskyi: Proteomic profiling of Diffuse Large B-cell Lymphomas. *Pathobiology* 2018, 85 (4):211-219.
58) J. Li, WX. Wen, M. Eklund, A. Kvist, M. Eriksson, H. Christensen, A. Torstensson, **S. Bajalica-Lagercrantz**, A. Dunning, C. Luccarini, K. Pooley, J. Simard, L. Dorling, D. Easton, S. Hwang Teo, P. Hall, A. Borg, H. Grönberg, and K. Czene: Prevalence of *BRCA1* and *BRCA2* pathogenic variants in a large, unselected breast cancer cohor. *Int J Cancer*. 2019, 144(5): 1195–1204.
59) J.R. Vos, L. Giepmans, C. Röhl, N. Geverink, N. Hoogerbrugge; ERN GENTURIS (**S. Bajalica-Lagercrantz**, Swedish coordinator): Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. *Familial Cancer* 2019, 18(2):281-284.
60) P. Kharaziha, S. Ceder, O. Axell, O. Fotouhi, M. Krall, M. S. Andersson, C. Larsson, D. Glaessgen, S. Lane, E. Tham, K. Wiman, **S. Bajalica-Lagercrantz**: Functional Characterization of novel germline TP53 variants in Swedish families. *Clinical Genetics* 2019, 96(3):216-225.
61) M. Omran, L. Blomqvist, Y. Brandberg, N. Pal, P. Kogner, A. Kinhult Ståhlbom, E. Tham, **S. Bajalica-Lagercrantz:** Whole-body MRI within a surveillance program for carriers with clinically actionable germline *TP53* variants - the

Swedish constitutional *TP53* study SWEP53. *Hereditary Cancer Clin Pract* 2020, 18:1.

62) T. Frebourg, **S. Bajalica-Lagercrantz**, C. Oliveira, R. Magenheim, DG Evans, the European Reference Network GENTURIS: Guidelines for the Li-Fraumeni and Heritable TP53-Related Cancer syndromes. *European Journal of Human Genetics*, 2020, 28:1379-1386.

63) GD. Evans, ER. Woodward, **S. Bajalica-Lagercrantz,** C. Oliveira, T. Frebourg: Germline TP53 Testing in Breast Cancers: Why, When and How? *Cancers* 2020, 12(12)3762-3776.

64) T. Frebourg, **S. Bajalica-Lagercrantz**, C. Oliveira, R. Magenheim, DG Evans, the European Reference Network GENTURIS: Reply to Kratz et al; Comment on Guidelines for the Li-Fraumeni and Heritable TP53-Related Cancer syndromes. *European Journal of Human Genetics*, 2020, 28:1483-1485.

65) M. Tischkowitz, C. Colas, S. Pouwels, N, Hoogerbrugge, ERN GENTURIS (**S. Bajalica-Lagercrantz**, Swedish coordinator): Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. *European journal of human genetics* 2020, 28 (10), 1387-1393.

66) D. Tamborero. R. Dienstmann, MH. Rachid, J. Boekel, R. Baird, I. Brana, L. De Petris, J. Yachnin, C. Massard, FL. Opdam, R. Schlenk, C. Vernieri, E. Garralda, M. Masucci, X. Villalobos, E. Chavarria, F. Calvo, S. Frohling, A. Eggermont, G. Apolone, EE. Voest, C. Caldas, J. Tabernero, I. Ernberg, Cancer Core Europe Consortium (including **S. Bajalica-Lagercrantz** 49 collaborators) J. Rodon, J. Lehtio: Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. *Nature medicine,* 2020, 26 (7), 992-994.

67) Y. Liu, O. Axell, T. van Leeuwen, R. Konrat, P. Kharaziha, C. Larsson, A. PH Wright, **S. Bajalica-Lagercrantz**. Association between predicted effects of *TP53* missense variants on protein conformation and their phenotypic presentation as Li-Fraumeni syndrome or hereditary breast cancer. *International journal of Molecular Sciences,* 2021, 22(12), 6345-6362.

68) D. Humberto Marmolejo, M. Yu Zheng Wong, **S. Bajalica-Lagercrantz,** M. Tischkowitz, J. Balmana, extended ERN-GENTURIS Thematic Group 3. Germline TP53 Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. *European Journal of Medical Genetics*, 2021, 64, 104350.

69) M. Omran, E.Tham, Y. Brandberg, H. Ahlström, C. Lundgren, Y. Paulsson-Karlsson, E. Kuchinskaya, G. Silander, A. Rosen, F. Persson, H. Leonhardt, M. Stenmark-Askmalm, D. van Westen, **S. Bajalica-Lagercrantz**, L Blomqvist. Whole-body MRI surveillance – Baseline findings in the Swedish multicenter hereditary *TP53*-related cancer syndrome study (SWEP53). *Cancers*, 2022, 14 (2), 380.

70) Y. Liu, HT. Helgadottir, P. Kharaziha, J. Choi, F. Lopez-Giraldez, SM. Mane, V. Höiom, CC. Juhlin, C. Larsson, S**. Bajalica-Lagercrantz.** Whole exome sequencing of germline variants in non-*BRCA* families with hereditary breast cancer. *Biomedicines*, 2022, 10 (5), 1004.

71) D. Tamborero, R. Dienstmann, M.H. Rachid, J. Boekel, A. Lopez-Fernandez, M. Jonsson, A. Razzak, I. Braña, L. De Petris, J. Yachnin, R.D. Baird, Y. Loriot, C. Massard, P. Martin-Romano, F. Opdam, R.F. Schlenk, C. Vernieri, M. Masucci, X. Villalobos, E. Chavarria; Cancer Core Europe Consortium (including **S. Bajalica-Lagercrantz** 49 collaborators), J. Balmaña, G. Apolone, C. Caldas, J. Bergh, I. Ernberg, S. Fröhling, E. Garralda, C. Karlsson, J. Tabernero, E. Voest, J. Rodon, J. Lehtiö. The Molecular Tumor Board Portal supports clinical

decisions and automated reporting for precision oncology. *Nature Cancer*. 2022, 3(2):251-261.

72) J. Garcia-Pelaez, R. Barbosa-Matos, S. Lobo, A. Dias, L. Garrido, S. Castedo, S. Sousa, H. Pinheiro, L. Sousa, R. Monteiro, J.J. Maqueda, S. Fernandes, F. Carneiro, N. Pinto, C. Lemos, C. Pinto, M.R. Teixeira, S. Aretz, **S. Bajalica-Lagercrantz**, J. Balmaña, A. Blatnik, P.R. Benusiglio, M. Blanluet, V. Bours, H. Brems, J. Brunet-Vidal, D. Calistri, G. Capellá, S. Carrera, C. Colas, K. Dahan, R. de Putter, C. Desseignés, E. Domínguez-Garrido, C. Egas, G. Evans, D. Feret, E. Fewings, R.C. Fitzgerald, F. Coulet, M. Garcia-Barcina, M. Genuardi, L. Golmard, K. Hackmann, H. Hanson, E. Holinski-Feder, R. Hüneburg, M. Krajc, K. Lagerstedt-Robinson, C. Lázaro, M. Ligtenberg, C. Martínez-Bouzas, S. Merino, G. Michils, S. Novakovic, A. Patiño-García, G.N. Ranzani, E. Schrock, I. Silva, C. Silveira, J.L. Soto, I. Spier, V. Steinke-Lange, G. Tedaldi, M-I. Tejada, E.R. Woodward, M. Tischkowitz, N. Hoogerbrugge, C. Oliveira. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes. *Lancet Oncolgy*, 2022, S1470-2045(22).

73) D. Tamborero, R. Dienstmann, M.H. Rachid, J. Boekel, A. Lopez-Fernandez, M. Jonsson, A. Razzak, I. Braña, L. De Petris, J. Yachnin, R.D. Baird, Y. Loriot, C. Massard, P. Martin-Romano, F. Opdam, R.F. Schlenk, C. Vernieri, M. Masucci, X. Villalobos, E. Chavarria; Cancer Core Europe Consortium (including **S. Bajalica-Lagercrantz** 49 collaborators), J. Balmaña, G. Apolone, C. Caldas, J. Bergh, I. Ernberg, S. Fröhling, E. Garralda, C. Karlsson, J. Tabernero, E. Voest, J. Rodon, J. Lehtiö. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. *Nature Cancer* 2022, 3(5):649.

74) R. Altena, **S. Bajalica-Lagercrantz**, A. Papakonstantinou. Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies. *Cancers*, 2022, 14 (19), 4665. Review.

75) M. Omran, H. Johansson, C. Lundgren, G. Silander, M. Stenmark-Askmalm, N. Loman, A. Baan, J. Adra, E. Kuchinskaya, L. Blomqvist, E. Tham, **S. Bajalica-Lagercrantz** Y. Brandberg & the Swedish Clinical *TP53* Study Group (SweClin*TP53*). Whole-body MRI surveillance in *TP53* carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer – data from the SWEP53 study. Cancer, 2023, 1-10.